APO866

APO866 (FK866) (0.09-27 nM) induces dose-dependent cytotoxicity in 41 hematologic malignant cells including acute myeloid leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphocytic leukemia, and T-cell lymphoma. APO866 (FK866) (0-10 nM) dose-dependently induces depletion of intracellular NAD and ATP contents and cell death in various hematologic cancer cells. APO866 (FK866) (10 nM) inhibits PBEF-induced secretion of MMP-3, CCL2, and CXCL8 in HFFF2 cells. APO866 administered intraperitoneally at dose of 20 mg/kg twice a day for 4 days, repeat weekly over 3 weeks, prevents and abrogats tumor growth in C.B.-17 SCID mice xenograft models of human AML, lymphoblastic lymphoma, and leukemia.